IRIDEX (NASDAQ:IRIX) Now Covered by StockNews.com

StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Monday morning. The firm issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Down 1.7 %

NASDAQ:IRIX opened at $1.77 on Monday. The firm has a market capitalization of $29.45 million, a P/E ratio of -2.70 and a beta of 0.80. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. IRIDEX has a one year low of $1.27 and a one year high of $3.65. The company’s 50-day simple moving average is $1.65 and its 200 day simple moving average is $1.97.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $11.58 million for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same period last year, the firm earned ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.